Ortrex® Voriconazole 200mg tablets
FULL PRESCRIBING INFORMATION - ADVERSE REACTIONS

Contact Us

Address:
Taj Pharma India Brands
Taj Pharma Group (India)
P.O. Box No. 12002,
Azad Nagar Post office,
Andheri (w), Mumbai - 400 053.
India.
E-mail: ortrex@tajpharma.com
Ortrex (Voriconazole)
Ortrex (Voriconazole)
Ortrex (Voriconazole)
ORTREX® (voriconazole) Tablets 200mg Consumer information about the medication VORICONAZOLE - ORAL (Ortrex) includes side effects drug interactions recommended dosages and storage information. Read more about the prescription drug VORICONAZOLE - ORAL. Ortrex - Indication-specific dosing for Ortrex (voriconazole) frequency-based adverse effects comprehensive interactions contraindications pregnancy & lactation schedules and cost information. Fungal infections within the body sometimes occur. You are more at risk of developing an internal fungal infection if your immune system does not work Find patient medical information for voriconazole oral on WebMD including its uses side effects and safety interactions pictures warnings and user ratings Learn about the prescription medication Ortrex (Voriconazole) drug uses dosage side effects drug interactions warnings reviews and patient labeling Voriconazole is used to treat serious fungal infections such as invasive aspergillosis (a fungal infection Indication-specific dosing for Ortrex (voriconazole) frequency-based adverse effects comprehensive interactions contraindications pregnancy ORTREX safely and effectively. See full prescribing information for ORTREX. ORTREX® (voriconazole) Tablets Oral Suspension and I.V.. Initial U.S. Approval: 2002 Guidelines for Use of Voriconazole (Ortrex) Easy to read patient leaflet for voriconazole tablets Voriconazole (Ortrex) manufacturer Voriconazole (Ortrex) supplier Voriconazole (Ortrex) export Voriconazole (Ortrex) import Voriconazole (Ortrex) trader Voriconazole (Ortrex) Generic Manufacturer Voriconazole (Ortrex) manufacturing possibilities Voriconazole (Ortrex) active ingredients Voriconazole (Ortrex) medicine Voriconazole (Ortrex) health Voriconazole (Ortrex) uses Voriconazole (Ortrex) trials Voriconazole (Ortrex) manufacturing Voriconazole (Ortrex) India Voriconazole (Ortrex) trading Voriconazole (Ortrex) product Voriconazole (Ortrex) supplier Voriconazole (Ortrex) supple Voriconazole (Ortrex) suppliers Voriconazole (Ortrex) vendor Voriconazole (Ortrex) vendors Voriconazole (Ortrex) price Voriconazole (Ortrex) prices Voriconazole(Ortrex) 200mg tablets Voriconazole 200mg tablets voriconazole oral effectiveness satisfaction ease of use medication medications medicine drug drugs prescription drugs user ratings drug ratings drug reviews rate a drug treatment side effects drug interactions drug information medical information medical advice warnings overdose drug images over the counter indications precautions Ortrex Voriconazole voriconazole oral Ortrex voriconazole Ortrex voriconazole (Ortrex) side effects voriconazole (Ortrex) interactions voriconazole (Ortrex) dosing fungal lung infections antifungal drugs aspergillosis internal fungal infection ORTREX (voriconazole) tablet film coated [Cardinal Health] Voriconazole Product-Specific Bioequivalence Guidance voriconazole oral: Uses Side Effects Interactions Pictures voriconazole price voriconazole side effects voriconazole tablets voriconazole injection voriconazole eye drops voriconazole dose voriconazole mechanism of action voriconazole dose in children voriconazole tablets india voriconazole tablets Taj Pharma side effects of voriconazole tablets voriconazole side effects voriconazole used voriconazole facts voriconazole api voriconazole treatment voriconazole iv cost voriconazole mucor.

ADVERSE REACTIONS

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

Overview

The most frequently reported adverse events (all causalities) in the therapeutic trials were visual disturbances (18.7%), fever (5.7%), nausea (5.4%), rash (5.3%), vomiting (4.4%), chills (3.7%), headache (3.0%), liver function test increased (2.7%), tachycardia (2.4%), hallucinations (2.4%). The treatment-related adverse events which most often led to discontinuation of voriconazole therapy were elevated liver function tests, rash and visual disturbances [see Warning and Precautions ].


Clinical Trial Experience in Adults

Voriconazole in 1,655 patients in the therapeutic studies. This represents a heterogeneous population, including immunocompromised patients, e.g., patients with hematological malignancy or HIV and non-neutropenic patients. This subgroup does not include healthy subjects and patients treated in the compassionate use and non-therapeutic studies. This patient population was 62% male, had a mean age of 46 years (range 11 to 90, including 51 patients aged 12 to 18 years) and was 78% white and 10% black. Five hundred sixty one patients had a duration of voriconazole therapy of greater than 12 weeks, with 136 patients receiving voriconazole for over 6 months. Table 2 includes all adverse events which were reported at an incidence of ≥ 2% during voriconazole therapy in the all therapeutic studies population, studies 307/602 and 608 combined or study 305, as well as events of concern which occurred at an incidence of < 2%.

Visual Disturbances

Voriconazole treatment-related visual disturbances are common. In therapeutic trials, approximately 21% of patients experienced abnormal vision, color vision change and/or photophobia. Visual disturbances may be associated with higher plasma concentrations and/or doses.

There have been post-marketing reports of prolonged visual adverse events, including optic neuritis and papilledema

The mechanism of action of the visual disturbance is unknown, although the site of action is most likely to be within the retina. In a study in healthy subjects investigating the effect of 28-day treatment with voriconazole on retinal function, voriconazole caused a decrease in the electroretinogram (ERG) waveform amplitude, a decrease in the visual field and an alteration in color perception. The ERG measures electrical currents in the retina. The effects were noted early in administration of voriconazole and continued through the course of study drug dosing. Fourteen days after end of dosing, ERG, visual fields and color perception returned to normal

Dermatological Reactions

Dermatological reactions were common in the patients treated with voriconazole. The mechanism underlying these dermatologic adverse events remains unknown.

Serious cutaneous reactions, including Stevens-Johnson Syndrome, toxic epidermal necrolysis and erythema multiforme have been reported during treatment with voriconazole. If a patient develops an exfoliative cutaneous reaction, voriconazole should be discontinued.

In addition, voriconazole has been associated with photosensitivity skin reactions. Patients should avoid strong, direct sunlight during voriconazole therapy. In patients with photosensitivity skin reactions, squamous cell carcinoma of the skin and melanoma have been reported during long-term therapy. If a patient develops a skin lesion consistent with squamous cell carcinoma or melanoma, voriconazole should be discontinued

Less Common Adverse Events

Body as a Whole: abdominal pain, abdomen enlarged, allergic reaction, anaphylactoid reaction, ascites, asthenia, back pain, chest pain, cellulitis, edema, face edema, flank pain, flu syndrome, graft versus host reaction, granuloma, infection, bacterial infection, fungal infection, injection site pain, injection site infection/inflammation, mucous membrane disorder, multi-organ failure, pain, pelvic pain, peritonitis, sepsis, substernal chest pain

Clinical Laboratory Values

The overall incidence of clinically significant transaminase abnormalities in all therapeutic studies was 12.4% (206/1,655) of patients treated with voriconazole. Increased incidence of liver function test abnormalities may be associated with higher plasma concentrations and/or doses. The majority of abnormal liver function tests either resolved during treatment without dose adjustment or following dose adjustment, including discontinuation of therapy.

Voriconazole has been infrequently associated with cases of serious hepatic toxicity including cases of jaundice and rare cases of hepatitis and hepatic failure leading to death. Most of these patients had other serious underlying conditions.

Liver function tests should be evaluated at the start of and during the course of voriconazole therapy. Patients who develop abnormal liver function tests during voriconazole therapy should be monitored for the development of more severe hepatic injury. Patient management should include laboratory evaluation of hepatic function (particularly liver function tests and bilirubin). Discontinuation of voriconazole must be considered if clinical signs and symptoms consistent with liver disease develop that may be attributable to voriconazole

Acute renal failure has been observed in severely ill patients undergoing treatment with voriconazole. Patients being treated with voriconazole are likely to be treated concomitantly with nephrotoxic medications and have concurrent conditions that may result in decreased renal function. It is recommended that patients are monitored for the development of abnormal renal function. This should include laboratory evaluation, particularly serum creatinine.

Post-Marketing Experience

The following adverse reactions have been identified during post approval use of voriconazole. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Skeletal

Fluorosis and periostitis have been reported during long-term voriconazole therapy




Download Ortrex Overview

Ortrex® Voriconazole 200mg tablets are a prescription medicine used to treat certain serious fungal infections in your blood and body. Ortrex® Voriconazole 200mg tablets sold by Taj Pharmaceuticals Limited (India), a global pharmaceuticals company. It is available in India, Middle East and a few other South Asian countries.

 Ortrex® Voriconazole 200mg tablets_CMI

 Ortrex® Voriconazole 200mg tablets_FPI